These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 6430496)
1. Effect of aluminum and parathyroid hormone on osteoblasts and bone mineralization in chronic renal failure. Dunstan CR; Evans RA; Hills E; Wong SY; Alfrey AC Calcif Tissue Int; 1984 Mar; 36(2):133-8. PubMed ID: 6430496 [TBL] [Abstract][Full Text] [Related]
2. Aluminum administration in the rat separately affects the osteoblast and bone mineralization. Rodriguez M; Felsenfeld AJ; Llach F J Bone Miner Res; 1990 Jan; 5(1):59-67. PubMed ID: 2309580 [TBL] [Abstract][Full Text] [Related]
4. Relationships between calcium and phosphorus homeostasis, parathyroid hormone levels, bone aluminum, and bone histomorphometry in patients on maintenance hemodialysis. Nilsson P; Melsen F; Malmaeus J; Danielson BG; Mosekilde L Bone; 1985; 6(1):21-7. PubMed ID: 2581596 [TBL] [Abstract][Full Text] [Related]
5. Biological effects of aluminum on normal dogs: studies on the isolated perfused bone. Galceran T; Finch J; Bergfeld M; Coburn J; Martin K; Teitelbaum S; Slatopolsky E Endocrinology; 1987 Jul; 121(1):406-13. PubMed ID: 3036473 [TBL] [Abstract][Full Text] [Related]
6. The evolution of osteomalacia in the rat with acute aluminum toxicity. Rodriguez M; Felsenfeld AJ; Llach F J Bone Miner Res; 1989 Oct; 4(5):687-96. PubMed ID: 2816514 [TBL] [Abstract][Full Text] [Related]
7. Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population. Andress DL; Maloney NA; Endres DB; Sherrard DJ J Bone Miner Res; 1986 Oct; 1(5):391-8. PubMed ID: 3503554 [TBL] [Abstract][Full Text] [Related]
8. The pathogenesis of renal osteodystrophy: role of vitamin D, aluminium, parathyroid hormone, calcium and phosphorus. Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Johnson JR; George CR; Collett P; Kalowski S Q J Med; 1985 May; 55(217):127-44. PubMed ID: 4001311 [TBL] [Abstract][Full Text] [Related]
9. The effect of high parathyroid hormone levels on the development of aluminum-induced osteomalacia in the rat. Felsenfeld AJ; Machado L; Rodriguez M J Am Soc Nephrol; 1991 Jan; 1(7):970-9. PubMed ID: 1883967 [TBL] [Abstract][Full Text] [Related]
10. Bone aluminum and histomorphometric features of renal osteodystrophy. Hodsman AB; Sherrard DJ; Alfrey AC; Ott S; Brickman AS; Miller NL; Maloney NA; Coburn JW J Clin Endocrinol Metab; 1982 Mar; 54(3):539-46. PubMed ID: 7056841 [TBL] [Abstract][Full Text] [Related]
11. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings. Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018 [TBL] [Abstract][Full Text] [Related]
12. Bone histologic response to deferoxamine in aluminum-related bone disease. Andress DL; Nebeker HG; Ott SM; Endres DB; Alfrey AC; Slatopolsky EA; Coburn JW; Sherrard DJ Kidney Int; 1987 Jun; 31(6):1344-50. PubMed ID: 2441107 [TBL] [Abstract][Full Text] [Related]
13. Evidence for a toxic effect of aluminum on osteoblasts: a histomorphometric study in hemodialysis patients with aplastic bone disease. Parisien M; Charhon SA; Arlot M; Mainetti E; Chavassieux P; Chapuy MC; Meunier PJ J Bone Miner Res; 1988 Jun; 3(3):259-67. PubMed ID: 3213621 [TBL] [Abstract][Full Text] [Related]
14. Osteomalacia and aplastic bone disease in aluminum-related osteodystrophy. Andress DL; Maloney NA; Coburn JW; Endres DB; Sherrard DJ J Clin Endocrinol Metab; 1987 Jul; 65(1):11-6. PubMed ID: 3584392 [TBL] [Abstract][Full Text] [Related]
15. Arterial calcifications and bone histomorphometry in end-stage renal disease. London GM; Marty C; Marchais SJ; Guerin AP; Metivier F; de Vernejoul MC J Am Soc Nephrol; 2004 Jul; 15(7):1943-51. PubMed ID: 15213285 [TBL] [Abstract][Full Text] [Related]
16. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment. Coen G; Mazzaferro S; Costantini S; Ballanti P; Carrieri MP; Giordano R; Smacchi A; Sardella D; Bonucci E; Taggi F Miner Electrolyte Metab; 1989; 15(5):295-302. PubMed ID: 2811788 [TBL] [Abstract][Full Text] [Related]
17. Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Sawaya BP; Butros R; Naqvi S; Geng Z; Mawad H; Friedler R; Fanti P; Monier-Faugere MC; Malluche HH Kidney Int; 2003 Aug; 64(2):737-42. PubMed ID: 12846773 [TBL] [Abstract][Full Text] [Related]
19. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Rojas E; Carlini RG; Clesca P; Arminio A; Suniaga O; De Elguezabal K; Weisinger JR; Hruska KA; Bellorin-Font E Kidney Int; 2003 May; 63(5):1915-23. PubMed ID: 12675872 [TBL] [Abstract][Full Text] [Related]
20. Can bone histomorphometry be predicted by clinical assessment and noninvasive techniques in peritoneal dialysis? Joffe P; Heaf JG; Jensen C Miner Electrolyte Metab; 1996; 22(4):224-33. PubMed ID: 8807626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]